Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Announces U.S. FDA Clearance of First Investigational New Drug Application for RLS-0071","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Peptide","graph2":"ReAlta Life Sciences"}]

ReAlta Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ReAlta Life Sciences Announces U.S. FDA Clearance of First Investigational New Drug Application for RLS-0071

Details:

ReAlta expects to begin a Phase 1 randomized, double-blind, placebo-controlled clinical trial of RLS-0071 in adult patients with pneumonia and early respiratory failure.

Lead Product(s): RLS-0071

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RLS-0071

Highest Development Status: IND Enabling Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 28, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY